3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
40
Gastro-enteropancreatic neuroendocrine tumor
8
Paraganglioma
6
Pheochromocytoma
5
Carcinoma, Neuroendocrine
4
Carcinoid Tumor
3
Neoplasms
2
Stomach Neoplasms
1
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Medulloblastoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hypertension
1
Interventions
telotristat ethyl
1
lutetium Lu 177 dotatate
1
lanreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Heart Disease
×
lutetium Lu 177 dotatate
×
Endocrine
×
Clear all
NCT04039516
2020-08-04
CHARRT
King's College Hospital NHS Trust
Phase 2
Unknown
20 enrolled